About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT01781117

Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia

Persistent detrusor overactivity (DO) after transurethral prostatectomy results in symptomatic failure in more than one third of the patients. Storage symptoms are major complaints in the early postop...

Lead sponsor: KYU-SUNG LEE•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

KYU-SUNG LEE

Collaborators

Samsung Medical Center

* Investigators are going to enroll age-matched control group and measure the urinary NGF levels as a baseline value (30 males). * Investigators are going to enroll BPO patients group (DO group 50 and Non-DO group 50 patients). * Administration of the anti-cholinergic agents was reported to decrease urinary NGF levels. Investigators are going to try to avoid the effect of anti-muscarinic drugs.

Age

50 - 80 years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•Male aged 50 yrs or greater
•International prostatic symptom score \>= 12
•Bladder outlet obstruction confirmed by pressure-flow study (BOOI \> 20)
•Ability and willingness to correctly complete the micturition diary and questionnaire
•Capable of understanding and having signed the informed consent form after full discussion of the research nature of the treatment and its risks and benefits

Exclusion Criteria

•Patients with urologic malignancies such as prostate cancer and bladder cancer
•Patients underwent urethral, prostate surgery
•Patients with urethral stricture or bladder diverticulum or bladder neck contracture
•Any other condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion

Related studies

Enrolling By Invitation

Migraine Medication Effects on Urinary Symptoms

NCT06212661 · Overactive Bladder, Bladder Pain Syndrome, and more

Transperineal Laser Ablation vs Transurethral Resection for Benign Prostatic Obstruction: A Randomized Clinical Trial

NCT04781049 · Prostate Hyperplasia, Benign Prostatic Hyperplasia, and more

Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor Overactivity

NCT01837654 · Overactive Detrusor

Onabotulinumtoxina Intradetrusorial Injections and NGF Expression

NCT01629433 · Overactive Detrusor, Detrusor Hyperreflexia of Bladder

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 2, 2019Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment184

Start dateFeb 2013

Last updatedDec 2, 2019

Condition

Benign Prostatic Hypertrophy With Outflow Obstruction Overactive Detrusor

Locations shown

Samsung Medical Center

Seoul

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 2, 2019Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions